<unk> , also known as nanoparticle albumin–bound<unk>  or nab-paclitaxel, is an injectable formulation of<unk>  used to treat breast cancer, lung cancer and pancreatic cancer, among others.<unk>  kills cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation,<unk>  is<unk> ed to albumin as a delivery vehicle. It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas". This treatment was approved in the United States in 2005, and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed. In 2012, the FDA widened the approved uses to include treatment for NSCLC. In 2013, the FDA approved<unk>  for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.
Protein-bound paclitaxel
Hypoxia-activated prodrug
Peripherally selective drug
Small molecule drug conjugate
Monoclonal antibody
Tissue-selective estrogen complex
Small modular immunopharmaceutical
Bisphosphonate